Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT003 Dose Ranging in COPD
NCT01587079Phase 2Completed
- Sponsor
- Pearl Therapeutics
- Start
- Apr 2012
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glycopyrrolate metered dose inhaler and formoterol fumarate in chronic obstructive pulmonary disease (COPD) (8 arms), sponsored by Pearl Therapeutics. Primary endpoint: Area Under the Curve for Forced Expiratory Volume in 1 Second from 0 to 12 hours. Started Apr 2012; status: completed.
02
Drugs
glycopyrrolate metered dose inhalerformoterol fumarate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01587079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01587079.